Aptevo Therapeutics Inc.
Built from the SEC filing index the day the filing landed. The figures below are the issuer's own from Form D; AltStreet's analysis, sponsor link and data flags follow when the entity is enriched.
Raised
$3M
Investors
3
Min Invest
None stated
Is this your company or fund? Claim this page free, or verify it and carry the Verified Issuer mark.
What this filing shows
·Every sentence is a value as filed on SEC Form D
Aptevo Therapeutics Inc. is a Delaware corporation that filed a Form D with the SEC on August 26, 2026 in the Pharmaceuticals industry group. The offering claims Rule 506(c) and covers equity. Aptevo Therapeutics Inc. reported $3,472,683 sold from 3 investors of a $3,472,683 total offering as of the Form D filed August 26, 2026. The offering relies on Rule 506(c), so the issuer may advertise it but may sell only to investors it has verified as accredited. The filing reports no non-accredited investors. The filing lists the minimum investment as $0, meaning no minimum was stated. The Form D names Roth Capital Partners, LLC (CRD 15407), associated with None as the recipient of sales compensation soliciting in all states. The issuer's address of record is 2401 4th Ave., Suite 1050, Seattle, WA 98121.
EDGAR Filing Data
Form D — Primary Source
View on SEC.govFilings on Record
Every filing AltStreet's ledger holds for this CIK, newest first. Each opens the SEC archive folder.
In the Terminal
Filing events
2
latest Aug 26, 2026
Critical / warning
0 / 0
0 watch · 2 info
Statements extracted
0
none on file
NAV prints
0
none on file
Offering chains
2
closed
Latest event New filer · Aug 26, 2026
SEC.govFund family Beneficially owned by BANK OF AMERICA CORP /DE/ · full family and the filing behind each link in the terminal
Investor
- The full fund family and 1 related vehicle (parallel, feeder, successor, sibling series) with the filing that shows each link
- 2 filing events with values and deltas, latest 2026-08-26, and alerts on the next one
- 2 offering timelines: velocity, share raised, first-sale lag, stalled flags
Pro
- This issuer against its cohort: rank by velocity and share raised among offerings filed the same quarter
- The same events, statements and NAV moves across every issuer, screenable, with unlimited watches and CSV
Counts and dates above are the free record. The values, the series and the comparisons are the seat. Loading your view…
Related Persons (Form D)
Executive officers, directors, and promoters listed on the SEC Form D filing. Source: SEC.gov.
Item 3 changed on the Form D filed 2026-08-26: 7 related persons added and 0 removed against the filing of 2025-04-18; 8 now listed. The names are in the Terminal feed.
Jeffrey G Lamothe
Executive Officer, Director · Seattle, WA
Marvin L White
Executive Officer, Director · Seattle, WA
Daphne Taylor
Executive Officer · Seattle, WA
John E Niederhuber
Director · Seattle, WA
Daniel J Abdun-Nabi
Director · Seattle, WA
Grady Grant III
Director · Seattle, WA
Zsolt Harsanyi
Director · Seattle, WA
Barbara Lopez Kunz
Director · Seattle, WA
Placement Agents and Sales Compensation (Form D)
Who the issuer reported paying to sell the securities (Form D Item 12), with the FINRA registration number the filer gave. Source: SEC.gov.
Roth Capital Partners, LLCCRD 15407 on BrokerCheck
Associated broker-dealer: None · Newport Beach, CA · Soliciting in all states
Questions About Aptevo Therapeutics Inc.
Each answer is built from the values on the SEC filing and the AltStreet ledger, not from the issuer's marketing.
What is Aptevo Therapeutics Inc.?
Aptevo Therapeutics Inc. is a Delaware corporation that filed a Form D with the SEC on August 26, 2026 in the Pharmaceuticals industry group. The filing claims Rule 506(c) for an offering of equity.
Is Aptevo Therapeutics Inc. legit?
AltStreet does not rate legitimacy; it reports the public record. Aptevo Therapeutics Inc. filed a Form D with the SEC on August 26, 2026 claiming Rule 506(c). A Form D is a notice of an exempt offering, not a review or approval of it. The newest notice reports $3,472,683 sold to 3 investors. AltStreet's enforcement record (SEC, FINRA and state actions) shows no action naming the issuer as of today. Before investing, confirm the filing on EDGAR, check the seller's registration on FINRA BrokerCheck, and read the offering documents, which a Form D does not include.
Is Aptevo Therapeutics Inc. registered with or approved by the SEC?
No. A Form D is a notice that an issuer is selling securities under an exemption from registration, and the SEC does not review, approve, or pass on the merits of the offering. The filing shows that Aptevo Therapeutics Inc. claimed Rule 506(c) and disclosed the items the form requires, such as the amount sold, the minimum investment, related persons, and anyone paid to sell the securities. It does not verify the issuer's claims or its business.
How much has Aptevo Therapeutics Inc. raised?
Aptevo Therapeutics Inc. reported $3,472,683 sold from 3 investors of a $3,472,683 total offering as of the Form D filed August 26, 2026.
Who can invest in Aptevo Therapeutics Inc.?
The offering relies on Rule 506(c), so the issuer may advertise it but may sell only to investors it has verified as accredited. The filing reports no non-accredited investors. The filing lists the minimum investment as $0, meaning no minimum was stated.
What is the minimum investment in Aptevo Therapeutics Inc.?
The Form D lists the minimum investment as $0, which means the issuer did not state a minimum on the form. The offering documents, not the Form D, set the actual subscription terms.
Who is selling Aptevo Therapeutics Inc. and how are they paid?
The Form D names Roth Capital Partners, LLC (CRD 15407), associated with None as the recipient of sales compensation soliciting in all states.
Who is behind Aptevo Therapeutics Inc.?
The Form D lists 8 related persons: Jeffrey G Lamothe, executive officer, director; Marvin L White, executive officer, director; Daphne Taylor, executive officer; John E Niederhuber, director; Daniel J Abdun-Nabi, director; Grady Grant III, director; Zsolt Harsanyi, director; Barbara Lopez Kunz, director. Form D Item 3 requires executive officers, directors, and promoters of the issuer to be listed.
Where is Aptevo Therapeutics Inc. located?
The issuer's address on its SEC filings is 2401 4th Ave., Suite 1050, Seattle, WA 98121. Its phone number of record is 206-838-0500. It is organized under the laws of Delaware.
How long is the Aptevo Therapeutics Inc. offering open?
The issuer indicated that the offering is not intended to last more than one year. An issuer must amend its Form D annually while a continuing offering stays open, and no amendment is on record yet.
What is Aptevo Therapeutics Inc.'s revenue?
The Form D reports a revenue range of No Revenues.

Is this your company or fund?
Free claim: add your contact details, website, team and a description to this page. The filed facts stay as filed.
Verified Issuer, $480 a year: AltStreet checks the identity of your company and the authority of the person claiming it against your filings, confirms your contact details on a stated date and again at each renewal, and marks the page so people researching you find a current, attributed profile beside the public filing record. It is not a review of any offering.
Data Methodology
Capital raise figures, investor counts, and filing dates are sourced directly from SEC EDGAR Form D primary documents via the SEC EDGAR submissions API and full-text search index. EDGAR entity profiles and deal-level data are reviewed by AltStreet analysts with backgrounds in corporate finance and securities law — cross-referenced against offering circulars, audited financial statements, and primary regulatory filings before publication. Platform-provided information, where present, is clearly labeled and does not affect EDGAR data or AltStreet editorial coverage. Platforms may request factual corrections for demonstrable inaccuracies by contacting [email protected]. This page does not constitute investment advice.
